Citations to this article
Tatiana A. Karakasheva, … , Dmitry I. Gabrilovich, Anil K. Rustgi
Published March 22, 2018
Citation Information: JCI Insight. 2018;3(6):e97022. https://doi.org/10.1172/jci.insight.97022.
Citation Information: JCI Insight. 2018;3(6):e97022. https://doi.org/10.1172/jci.insight.97022.
Abstract
BACKGROUND. Myeloid-derived suppressor cells (MDSCs) are a population of immature immune cells with several protumorigenic functions. CD38 is a transmembrane receptor–ectoenzyme expressed by MDSCs in murine models of esophageal cancer. We hypothesized that CD38 could be expressed on MDSCs in human colorectal cancer (CRC), which might allow for a new perspective on therapeutic targeting of human MDSCs with anti-CD38 monoclonal antibodies in this cancer. METHODS. Blood samples were collected from 41 CRC patients and 8 healthy donors, followed by peripheral blood mononuclear cell (PBMC) separation. Polymorphonuclear (PMN-) and monocytic (M-) MDSCs and CD38 expression levels were quantified by flow cytometry. The immunosuppressive capacity of M-MDSCs from 10 CRC patients was validated in a mixed lymphocyte reaction (MLR) assay. RESULTS. A significant expansion of CD38+ M-MDSCs and a trend of expansion of CD38+ PMN-MDSCs (accompanied by a trend of increased CD38 expression on both M- and PMN-MDSCs) were observed in PBMCs of CRC patients when compared with healthy donors. The CD38+ M-MDSCs from CRC patients were found to be immunosuppressive when compared with mature monocytes. CD38+ M- and PMN-MDSC frequencies were significantly higher in CRC patients who previously received treatment when compared with treatment-naive patients. CONCLUSIONS. This study provides a rationale for an attempt to target M-MDSCs with an anti-CD38 monoclonal antibody in metastatic CRC patients. FUNDING. NCI P01-CA14305603, the American Cancer Society, Scott and Suzi Lustgarten Family Colon Cancer Research Fund, Hansen Foundation, and Janssen Research and Development.
Authors
Tatiana A. Karakasheva, George A. Dominguez, Ayumi Hashimoto, Eric W. Lin, Christopher Chiu, Kate Sasser, Jae W. Lee, Gregory L. Beatty, Dmitry I. Gabrilovich, Anil K. Rustgi
Total citations by year
Citation information
Citations to this article (52)
| Title and authors | Publication | Year |
|---|---|---|
|
Tumor suppressors in Sox2-mediated lung cancers promote distinct cell intrinsic and immunologic remodeling
Nisitha Sengottuvel, Weida Gong, Jennifer Modliszewski, Allison Woods, Eric Livingston, Rani Sellers, Katerina Fagan-Solis, Gabrielle Cannon, Lincy Edatt, Kristina Whately, Hong Yuan, Virginia Godfrey, Gaorav Gupta, Chad Pecot |
JCI Insight | 2025 |
|
Harnessing myeloid cells in cancer
Park SY, Pylaeva E, Bhuria V, Gambardella AR, Schiavoni G, Mougiakakos D, Kim SH, Jablonska J |
Molecular Cancer | 2025 |
|
Immunometabolism of Innate Immune Cells in Gastrointestinal Cancer
Siemińska I, Lenart M |
Cancers | 2025 |
|
CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer
Wang W, Liu X, Xu S, Dai E, Li Y, Liu Y, Shan L, Li Y |
Translational Oncology | 2025 |
|
A high proportion of CD38 (high) CD16 (low) NK cells in colorectal cancer can interrupt immune surveillance and favor tumor growth
Wang X, Li L, Song X, Fang K, Chang X |
Cancer Immunology, Immunotherapy : CII | 2025 |
|
Epigenomic preconditioning of peripheral monocytes determines their transcriptional response to the tumor microenvironment
Kiss M, Halasz L, Hadadi E, Berger WK, Tzerpos P, Poliska S, Kancheva D, Gabriel A, Mora Barthelmess R, Debraekeleer A, Brughmans J, Elkrim Y, Martens L, Saeys Y, Daniel B, Czimmerer Z, Laoui D, Nagy L, Van Ginderachter JA |
Genome Medicine | 2025 |
|
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors
Pettinella F, Mariotti B, Lattanzi C, Bruderek K, Donini M, Costa S, Marini O, Iannoto G, Gasperini S, Caveggion E, Castellucci M, Calzetti F, Bianchetto-Aguilera F, Gardiman E, Giani M, Dusi S, Cantini M, Vassanelli A, Pavone D, Milella M, Pilotto S, Biondani P, Höing B, Schleupner MC, Hussain T, Hadaschik B, Kaspar C, Visco C, Tecchio C, Koenderman L, Bazzoni F, Tamassia N, Brandau S, Cassatella MA, Scapini P |
Cell reports. Medicine | 2024 |
|
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade.
Fortin BM, Pfeiffer SM, Insua-Rodríguez J, Alshetaiwi H, Moshensky A, Song WA, Mahieu AL, Chun SK, Lewis AN, Hsu A, Adam I, Eng OS, Pannunzio NR, Seldin MM, Marazzi I, Marangoni F, Lawson DA, Kessenbrock K, Masri S |
Nature Immunology | 2024 |
|
Neutrophil-like Monocytes Increase in Patients with Colon Cancer and Induce Dysfunctional TIGIT+ NK Cells
Calabrò A, Drommi F, Sidoti Migliore G, Pezzino G, Vento G, Freni J, Costa G, Cavaliere R, Bonaccorsi I, Sionne M, Nigro S, Navarra G, Ferlazzo G, De Pasquale C, Campana S |
International journal of molecular sciences | 2024 |
|
CD38 as theranostic target in oncology.
Valentina B, Jessica B, Michelle P, Nadia W, Roland H, Matthias D, Jo C, Guillaume M |
Journal of translational medicine | 2024 |
|
CD38 modulates cytokine secretion by NK cells through the Sirt1/NF-κB pathway, suppressing immune surveillance in colorectal cancer.
Wang X, Song X, Fang K, Chang X |
Scientific reports | 2024 |
|
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.
Stagg J, Golden E, Wennerberg E, Demaria S |
Science Immunology | 2023 |
|
Targeting M-MDSCs enhances the therapeutic effect of BNCT in the 4-NQO-induced murine head and neck squamous cell carcinoma model
Chang CH, Chen CJ, Yu CF, Tsai HY, Chen FH, Chiang CS |
Frontiers in Oncology | 2023 |
|
Implications of Rectal Cancer Radiotherapy on the Immune Microenvironment: Allies and Foes to Therapy Resistance and Patients’ Outcome
Sartorius D, Blume ML, Fleischer JR, Ghadimi M, Conradi LC, De Oliveira T |
Cancers | 2023 |
|
Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets
Al-Mterin MA, Elkord E |
2022 | |
|
Mass cytometry reveals immune atlas of urothelial carcinoma
Zhang Q, Zhang W, Lin T, Lu W, He X, Ding Y, Chen W, Diao W, Ding M, Shen P, Guo H |
BMC Cancer | 2022 |
|
Targeting CD38 in Neoplasms and Non-Cancer Diseases
Szlasa W, Czarny J, Sauer N, Rakoczy K, Szymańska N, Stecko J, Kołodziej M, Kaźmierczak M, Barg E |
Cancers | 2022 |
|
Single-cell transcriptome profiling reveals heterogeneous neutrophils with prognostic values in sepsis.
Hong Y, Chen L, Sun J, Xing L, Yang Y, Jin X, Cai H, Dong L, Zhou L, Zhang Z |
iScience | 2022 |
|
Evolving roles of CD38 metabolism in solid tumour microenvironment.
Gao L, Du X, Li J, Qin FX |
British Journal of Cancer | 2022 |
|
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Christofides A, Katopodi XL, Cao C, Karagkouni D, Aliazis K, Yenyuwadee S, Aksoylar HI, Pal R, Mahmoud MA, Strauss L, Tijaro-Ovalle NM, Boon L, Asara J, Vlachos IS, Patsoukis N, Boussiotis VA |
Nature Immunology | 2022 |
|
A decreased preoperative platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value are associated with the poorer survival of patients with a stent inserted as a bridge to curative surgery for obstructive colorectal cancer.
Sato R, Oikawa M, Kakita T, Okada T, Abe T, Tsuchiya H, Akazawa N, Ohira T, Harada Y, Okano H, Ito K, Tsuchiya T |
Surgery Today | 2022 |
|
The role of myeloid‐derived suppressor cells in gastrointestinal cancer
C Cui, P Lan, L Fu |
2021 | |
|
Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment
J Frosch, I Leontari, J Anderson |
Cancers | 2021 |
|
Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad
Y Ge, D Cheng, Q Jia, H Xiong, J Zhang |
Immune Network | 2021 |
|
CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint
Z Ding, Y He, Y Fu, N Zhu, M Zhao, Y Song, X Huang, S Chen, Y Yang, C Zhang, Q Hu, Y Ni, L Ding |
Frontiers in Oncology | 2021 |
|
Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis
X Yan, Y Xie, F Yang, Y Hua, T Zeng, C Sun, M Yang, X Huang, H Wu, Z Fu, W Li, S Jiao, Y Yin |
Journal of Experimental & Clinical Cancer Research | 2021 |
|
CD38 in Advanced Prostate Cancers
C Guo, M Crespo, B Gurel, D Dolling, J Rekowski, A Sharp, A Petremolo, S Sumanasuriya, DN Rodrigues, A Ferreira, R Pereira, I Figueiredo, N Mehra, MB Lambros, A Neeb, V Gil, G Seed, L Terstappen, A Alimonti, CG Drake, W Yuan, JS de Bono, D Robinson, EM Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, B Montgomery, ME Taplin, CC Pritchard, G Attard, H Beltran, W Abida, RK Bradley, J Vinson, X Cao, P Vats, LP Kunju, M Hussain, SA Tomlins, KA Cooney, DC Smith, C Brennan, J Siddiqui, R Mehra, Y Chen, DE Rathkopf, MJ Morris, SB Solomon, JC Durack, VE Reuter, A Gopalan, J Gao, M Loda, RT Lis, M Bowden, SP Balk, G Gaviola, C Sougnez, M Gupta, EY Yu, EA Mostaghel, HH Cheng, H Mulcahy, LD True, SR Plymate, H Dvinge, R Ferraldeschi, P Flohr, S Miranda, Z Zafeiriou, N Tunariu, J Mateo, R Perez-Lopez, F Demichelis, BD Robinson, M Schiffman, DM Nanus, ST Tagawa, A Sigaras, KW Eng, O Elemento, A Sboner, EI Heath, HI Scher, KJ Pienta, P Kantoff, JS de Bono, MA Rubin, PS Nelson, LA Garraway, CL Sawyers, AM Chinnaiyan |
European Urology | 2021 |
|
Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer
G Colombo, EL Gelardi, FC Balestrero, M Moro, C Travelli, AA Genazzani |
Frontiers in pharmacology | 2021 |
|
Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review)
A Lampis, M Ratti, M Ghidini, M Mirchev, A Okuducu, N Valeri, J Hahne |
International journal of molecular medicine | 2021 |
|
TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer
Gneo L, Rizkalla N, Hejmadi R, Mussai F, de Santo C, Middleton G |
Cancer Immunology, Immunotherapy | 2021 |
|
The Engagement Between MDSCs and Metastases: Partners in Crime
R Trovato, S Canè, V Petrova, S Sartoris, S Ugel, FD Sanctis |
Frontiers in Oncology | 2020 |
|
Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment
V Davidov, G Jensen, S Mai, SH Chen, PY Pan |
Frontiers in immunology | 2020 |
|
Tumor immune microenvironment in head and neck cancers
SM Chen, AL Krinsky, RA Woolaver, X Wang, Z Chen, JH Wang |
Molecular Carcinogenesis | 2020 |
|
Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche P Han, P Cao, S Hu, K Kong, Y Deng, B Zhao, F Li |
Cancer management and research | 2020 |
|
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
AM Law, F Valdes-Mora, D Gallego-Ortega |
Cells | 2020 |
|
Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression
K Yin, X Xia, K Rui, T Wang, S Wang |
Frontiers in Oncology | 2020 |
|
CD38: T Cell Immuno-Metabolic Modulator
A Kar, S Mehrotra, S Chatterjee |
Cells | 2020 |
|
Myeloid-Derived Suppressor Cells in Colorectal Cancer
I Sieminska, J Baran |
Frontiers in immunology | 2020 |
|
The Generation and Identity of Human Myeloid-Derived Suppressor Cells
C Bergenfelz, K Leandersson |
Frontiers in Oncology | 2020 |
|
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
G Fucà, V Guarini, C Antoniotti, F Morano, R Moretto, S Corallo, F Marmorino, S Lonardi, L Rimassa, A Sartore-Bianchi, B Borelli, M Tampellini, S Bustreo, M Claravezza, A Boccaccino, R Murialdo, A Zaniboni, G Tomasello, F Loupakis, V Adamo, G Tonini, E Cortesi, F de Braud, C Cremolini, F Pietrantonio |
British Journal of Cancer | 2020 |
|
Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
L Cassetta, K Bruderek, J Skrzeczynska-Moncznik, O Osiecka, X Hu, IM Rundgren, A Lin, K Santegoets, U Horzum, A Godinho-Santos, G Zelinskyy, T Garcia-Tellez, S Bjelica, B Taciak, AO Kittang, B Höing, S Lang, M Dixon, V Müller, JS Utikal, D Karakoç, KB Yilmaz, E Górka, L Bodnar, OE Anastasiou, C Bourgeois, R Badura, M Kapinska-Mrowiecka, M Gotic, M ter Laan, E Kers-Rebel, M Król, JF Santibañez, M Müller-Trutwin, U Dittmer, AE de Sousa, G Esendağlı, G Adema, K Loré, E Ersvær, V Umansky, JW Pollard, J Cichy, S Brandau |
Journal for ImmunoTherapy of Cancer | 2020 |
|
The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
E Calabretta, C Carlo-Stella |
Cells | 2020 |
|
Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma
X Pang, H Fan, Y Tang, S Wang, M Cao, H Wang, L Dai, K Wang, X Yu, J Wu, YJ Tang, X Liang, CC Yu |
PloS one | 2020 |
|
The association between monocytic myeloid-derived suppressor cells levels and the anti-tumor efficacy of anti-PD-1 therapy in NSCLC patients
J Feng, S Chen, S Li, B Wu, J Lu, L Tan, J Li, Y Song, G Shi, YG Shi, J Jiang |
Translational oncology | 2020 |
|
Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer
A Jayakumar, AL Bothwell |
Journal of immunology (Baltimore, Md. : 1950) | 2019 |
|
Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
BA Abolarinwa, RB Ibrahim, YH Huang |
International journal of molecular sciences | 2019 |
|
Neutrophil Diversity in Health and Disease
C Silvestre-Roig, ZG Fridlender, M Glogauer, P Scapini |
Trends in Immunology | 2019 |
|
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
J Wagner, MA Rapsomaniki, S Chevrier, T Anzeneder, C Langwieder, A Dykgers, M Rees, A Ramaswamy, S Muenst, SD Soysal, A Jacobs, J Windhager, K Silina, M van den Broek, KJ Dedes, MR Martínez, WP Weber, B Bodenmiller |
Cell | 2019 |
|
MicroRNA networks regulate the differentiation, expansion and suppression function of myeloid-derived suppressor cells in tumor microenvironment
Y Su, Y Qiu, Z Qiu, P Qu |
Journal of Cancer | 2019 |
|
A good start of immunotherapy in esophageal cancer
Q Zhao, J Yu, X Meng |
Cancer Medicine | 2019 |
|
The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors
JM Konen, JJ Fradette, DL Gibbons |
Cells | 2019 |
|
The Yin and Yang of Myeloid Derived Suppressor Cells
S Budhwar, P Verma, R Verma, S Rai, K Singh |
Frontiers in immunology | 2018 |
